Background. Chronic limb-threatening ischaemia (CLTI) is the most severe manifestation of peripheral arterial disease (PAD), and is associated with poor prognosis and high amputation rates. Novel therapeutic approaches are currently being investigated, but to date, they have not demonstrated significant benefits in promoting CLTI limb salvage. Understanding the molecular pathways of skeletal muscle dysfunction in CLTI is imperative for a rational design of successful therapeutic approaches. The full spectrum of dysregulated microRNAs (miRNAs) associated with PAD disease stages is currently poorly understood. The purpose of this study was to identify dysregulated miRNA transcripts in gastrocnemius muscle biopsies that were differentially expressed in different PAD cohorts.
Methods. We performed an analysis of a publicly available RNA-sequencing database of PAD cohorts using MIcroRNA ENrichment TURned NETwork(MIENTURNET), a web tool for miRNA-target enrichment and network-based analysis. Following this, we validated the dysregulation of miRNAs and their targets in mice with hindlimb ischaemia (HLI).
Results. Our miRNA-target interaction enrichment analysis identified a list of miRNAs over-represented amongst upregulated differentially expressed genes (DEGs) in CLTI. Upon validation in the HLI model, our results showed a significant and marked ischaemia-induced decrease of miR-1, miR-133a, and miR-29b in the ischaemic limbs vs the contralateral non-ischaemic limbs. A miR-1, miR-133a, and miR-29b target protein-protein interaction network identified many extracellular matrix components including collagen-1a1, -3a1 and -4a1, fibronectin-1, fibrin-1, matrix metalloproteinase-2 and -14, and the secreted protein acidic and rich in cysteine (Sparc), which were upregulated in the ischaemic muscle in mice. Functional enrichment analysis performed on this subset of DEGs identified pathways related to fibrosis and vascular pathology.
Conclusions. We have identified, for the first time, a CLTI-specific miRNA signature. Our results indicate miR-1, miR-133a, and miR-29b as potential contributors to the fibrosis and vascular pathology in CLTI muscle, which supports its investigation as potential novel therapeutics.